Qianshan L. Tao

Hefei, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications

Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma.

Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma.

Journal: Frontiers in oncology
Published: June 30, 2026

Multi-omics integration of molecular genetics, cytogenetics and immunophenotyping: a novel prognostic model for immune landscape characterization and outcome prediction in Chinese patients with acute myeloid leukemia.

Multi-omics integration of molecular genetics, cytogenetics and immunophenotyping: a novel prognostic model for immune landscape characterization and outcome prediction in Chinese patients with acute myeloid leukemia.

Journal: Frontiers in immunology
Published: February 17, 2026

An early integrated prognostic system for predicting relapse and guiding intervention post-CD19 CAR-T therapy in B-cell acute lymphoblastic leukaemia.

An early integrated prognostic system for predicting relapse and guiding intervention post-CD19 CAR-T therapy in B-cell acute lymphoblastic leukaemia.

Journal: British journal of haematology
Published: January 18, 2026

Co-expression of CCR7 and H3K9me3 identifies aggressive B-cell lymphoma with bone marrow infiltration and poor prognosis.

Co-expression of CCR7 and H3K9me3 identifies aggressive B-cell lymphoma with bone marrow infiltration and poor prognosis.

Journal: European cytokine network
Published: December 18, 2025

The impact of venetoclax treatment duration on efficacy and hematologic toxicity in acute myeloid leukemia: a systematic review and meta-analysis.

The impact of venetoclax treatment duration on efficacy and hematologic toxicity in acute myeloid leukemia: a systematic review and meta-analysis.

Journal: Annals of hematology
Published: September 19, 2025

Targeting CCR7-KMT2D enhances CAR-T cell efficacy by suppressing therapy-induced senescence in B-cell non-Hodgkin lymphoma.

Targeting CCR7-KMT2D enhances CAR-T cell efficacy by suppressing therapy-induced senescence in B-cell non-Hodgkin lymphoma.

Journal: BMC medicine
Published: July 27, 2025

CBX7 regulates chemotherapy-induced senescence-like growth arrest in multiple myeloma via the ERK/STAT3/PIM1 axis.

CBX7 regulates chemotherapy-induced senescence-like growth arrest in multiple myeloma via the ERK/STAT3/PIM1 axis.

Journal: Journal of translational medicine
Published: July 03, 2025

Identification and construction of a novel NET-related gene signature for predicting prognosis in multiple myeloma.

Identification and construction of a novel NET-related gene signature for predicting prognosis in multiple myeloma.

Journal: Clinical and experimental medicine
Published: January 14, 2025

Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status.

Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status.

Journal: Scientific reports
Published: January 12, 2025

Ribosomal protein L5 induces cellular senescence via p53-p21-pRb pathway to mediate relapse of acute myeloid leukemia.

Ribosomal protein L5 induces cellular senescence via p53-p21-pRb pathway to mediate relapse of acute myeloid leukemia.

Journal: Scientific reports
Published: November 29, 2024

Chemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin's lymphoma via CCR7/ARHGAP18/IKBα signaling activation.

Chemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin's lymphoma via CCR7/ARHGAP18/IKBα signaling activation.

Journal: Journal for immunotherapy of cancer
Published: November 23, 2024

Genetic Response of Chronic Neutrophilic Leukemia With CSF3R T618I, SETBP1, and ASXL1 Mutations After Decitabine Therapy.

Genetic Response of Chronic Neutrophilic Leukemia With CSF3R T618I, SETBP1, and ASXL1 Mutations After Decitabine Therapy.

Journal: American journal of therapeutics
Published: September 18, 2024
Showing 1-12 of 60

Last Updated: 09/26/2026